pHion Therapeutics Ltd.

What pHion Therapeutics Ltd. does

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotechnology company founded in 2017 and headquartered in Belfast, focused on developing next-generation mRNA vaccines. The company's core asset is its proprietary RALA delivery platform, designed to improve the delivery efficiency and stability of mRNA vaccines relative to conventional lipid-based delivery systems. RALA underpins the company's pipeline, which targets both oncology and infectious disease indications. The lead candidate, PTX_V1, is advancing into clinical trials in 2024.

The company's go-to-market motion is partnership- and licensing-driven, typical of a clinical-stage biotech: pHion develops the technology and pipeline internally, then seeks co-development partnerships, licensing agreements, and royalty arrangements with larger pharmaceutical companies, with eventual product sales following regulatory approval. Revenue model types include licensing and royalties. The company is pre-revenue and has no publicly disclosed customers or commercial products at this stage.

Capital has come from a narrow investor base, including QUBIS in January 2020 and a second investment tranche from invoX Pharma Limited in June 2023, the latter specifically funding clinical development of PTX_V1 and expansion of the RALA platform. Leadership is anchored by founder and CEO Helen McCarthy and Chief Operating Officer Darach Neeson. Operating geographies are concentrated in the United Kingdom. Note: the company's listed website domain (phiontx.co.uk) currently displays third-party casino affiliate content unrelated to pHion's biotech operations, which warrants verification of the company's actual web presence.

Name

pHion Therapeutics Ltd.

Website

https://phiontx.co.uk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotech developing next-generation mRNA vaccines using its proprietary RALA delivery platform for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• MRNA vaccine development
• Drug delivery platform
• Targeted nanoparticles
• Cancer immunotherapy
• Infectious disease vaccines

Headquarters

HQ city

Belfast

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Vaccine Development and Licensing: Pre-revenue clinical-stage biotech developing mRNA vaccines for oncology and infectious diseases. Revenue will likely come from licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Go-to-market motion1 record

Core offering

pHion Therapeutics Ltd. is a clinical-stage biotechnology company developing next-generation mRNA vaccines using its proprietary RALA delivery platform. The company focuses on improving the efficiency and stability of mRNA vaccines for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024. Revenue is anticipated through licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Product overview

pHion Therapeutics Ltd. is a UK-based company developing next-generation mRNA vaccines. The company's core technology consists of the proprietary RALA platform for mRNA vaccine delivery, which improves delivery efficiency and stability. The lead product candidate is PTX_V1, which is advancing into clinical trials in 2024 as part of a clinical pipeline focused on oncology and infectious disease vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• PTX_V1

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• BioNTech: Global leader in mRNA therapeutics and the dominant commercial mRNA vaccine player via Comirnaty. Directly comparable as an mRNA platform developer pursuing oncology and infectious-disease indications, but operates at vastly larger scale with validated products, capital, and clinical infrastructure that dwarf pHion's pre-clinical-stage RALA platform.
• Moderna: Major mRNA therapeutics company with Spikevax and an extensive pipeline spanning oncology vaccines (e.g., mRNA-4157) and infectious diseases. Highly comparable to pHion in target indications (oncology + infectious disease), but operates as the publicly-listed incumbent defining the mRNA delivery benchmark pHion's RALA platform would need to beat.
• GlaxoSmithKline (GSK) Vaccines: Global vaccine incumbent that routinely licenses or in-licenses novel vaccine technologies and adjuvant/delivery platforms. Relevant potential strategic acquirer/partner for pHion's RALA-based oncology and infectious-disease vaccines, comparable to invoX's role today.
• Sanofi Vaccines: Major vaccine franchise with active mRNA strategy (including the Translate Bio acquisition and its own mRNA programs). Represents the type of strategic partner likely to evaluate RALA for in-licensing and serves as a benchmark acquirer profile similar to invoX.

Direct peers

• CureVac: German mRNA therapeutics company developing optimized mRNA constructs and proprietary delivery approaches for oncology and prophylactic vaccines. Closely comparable in stage and business model - pre-commercial mRNA platform targeting similar indications - making it one of the most relevant benchmark peers for pHion's RALA technology.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with a proprietary lipid-mediated delivery platform (LUNAR) and pipeline spanning infectious disease and oncology vaccines. Structurally analogous to pHion: delivery-platform differentiation, dual indication strategy, and licensing/partnering revenue model with large pharma.
• Translate Bio (Sanofi): Pre-acquisition developer of an mRNA delivery platform (LUNAR-like lipid nanoparticles) targeting infectious disease and rare diseases; acquired by Sanofi in 2021 for ~$3.2B. Provides a useful comp on how Big Pharma values differentiated mRNA delivery platforms - the exit path pHion could pursue with invoX or other strategics.

Emerging players

• eTheRNA immunotherapies: Belgian clinical-stage biotech developing mRNA-based immunotherapies with proprietary delivery and immune-stimulation technology for oncology and infectious diseases. Closely comparable peer in geography, stage, and therapeutic focus, offering a useful benchmark on European mRNA vaccine platform deal terms and clinical trajectories.
• Ethris: Germany-based biotech developing SNIM® RNA-based therapeutics with proprietary stabilization and pulmonary delivery technology. Relevant peer in the stable, non-LNP RNA delivery space where pHion's RALA also competes, addressing similar respiratory and protein-replacement indications.
• Ziphius Vaccines: European clinical-stage biotech developing self-amplifying RNA (saRNA) vaccines and proprietary delivery technology for infectious disease and rare diseases. Comparable as a small, platform-driven mRNA vaccine company pursuing licensing partnerships with larger pharma.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/phiontx

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pHion Therapeutics Ltd.